0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diagnostic Substances Market by Product Type, End-User, Application - Global Forecast to 2030- Product Image
Diagnostic Substances Market by Product Type, End-User, Application - Global Forecast to 2030- Product Image
Sale

Diagnostic Substances Market by Product Type, End-User, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015434
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diagnostic Substances Market grew from USD 178.36 billion in 2024 to USD 189.53 billion in 2025. It is expected to continue growing at a CAGR of 6.48%, reaching USD 259.99 billion by 2030.

Setting the Stage for Diagnostic Substances Market Evolution

The diagnostic substances market stands at a pivotal juncture where rapid technological advancements, shifting regulatory frameworks, and evolving end-user demands converge to redefine industry standards. Over the past decade, breakthroughs in molecular diagnostics, point-of-care testing, and bioinformatics have accelerated the development of sophisticated instruments, precision assays, and specialized reagents that enable faster, more accurate disease detection and monitoring. These capabilities are reshaping the healthcare paradigm by facilitating earlier intervention, personalized treatment protocols, and enhanced patient outcomes.

Against this backdrop, market stakeholders face increasing pressure to innovate while maintaining cost efficiency and regulatory compliance. Investors, manufacturers, and healthcare providers must navigate complex supply chains, emerging trade policies, and intense competition from new entrants leveraging digital platforms. This executive summary distills the latest trends, structural shifts, and strategic imperatives affecting the diagnostic substances landscape. It provides decision-makers with a clear understanding of market drivers, segmentation dynamics, regional performance, and competitive behavior essential for charting a sustainable growth trajectory.

Emerging Forces Reshaping the Diagnostic Substances Landscape

The landscape of diagnostic substances is undergoing transformative shifts driven by converging advances in molecular biology, data analytics, and manufacturing flexibility. Miniaturization of laboratory platforms has given rise to portable imaging systems and integrated analyzers that extend diagnostic reach into ambulatory and remote care settings. At the same time, real-time PCR and next-generation sequencing platforms have become more accessible through streamlined workflows and reagent kits optimized for speed and reliability.

In parallel, the integration of artificial intelligence and machine learning into data interpretation has enhanced the precision of assay results, reducing false positives and optimizing clinical decision support. Regulatory agencies are streamlining approval pathways for high-impact diagnostics, fostering faster commercialization cycles. Moreover, the COVID-19 pandemic catalyzed widespread adoption of rapid test kits and lateral flow assays, creating lasting demand for flexible, scalable production models. Collectively, these forces are driving a new era of diagnostic innovation where agility, connectivity, and cross-disciplinary collaboration define success.

Assessing the Ripple Effects of 2025 United States Tariffs

The introduction of United States tariffs on a broad range of imported diagnostic substances in 2025 has generated a cascade of cost pressures and supply chain realignments across the industry. Manufacturers reliant on overseas components for instruments, assay kits, and specialized reagents have faced escalating input costs, prompting a reassessment of pricing strategies and supplier relationships. These additional duties have been cumulatively absorbed by value chain participants or passed on to end users depending on contractual flexibility and competitive positioning.

In response, several firms accelerated regional diversification of their production networks, establishing or expanding manufacturing hubs in tariff-exempt markets to mitigate duty burdens. Others pursued strategic stockpiling and long-term procurement contracts to lock in favorable terms. While short-term headwinds have strained profitability for certain players, the structure of these tariffs has also incentivized investment in domestic production capabilities, potentially reducing future vulnerability to trade disruptions. The net effect underscores the importance of adaptive sourcing models and proactive policy analysis in safeguarding operational resilience.

Unveiling Market Segments Driving Diagnostic Substances Demand

A thorough segmentation of the diagnostic substances market reveals distinctive growth drivers and innovation pathways across product categories, user environments, and application domains. In the realm of instruments, high-throughput analyzers, advanced imaging platforms, and molecular diagnostic systems-including next-generation sequencing and polymerase chain reaction machines-remain the backbone of laboratory and clinical workflows. These platforms command premium valuations and yield robust service revenue through consumables and maintenance agreements.

Meanwhile, the kits and assays segment, encompassing enzyme-linked immunosorbent assay formats, lateral flow tests, PCR-based panels, and rapid diagnostics, continues to thrive on demand for decentralized testing solutions. The agility of these assay formats has proven essential in infectious disease detection and preventative health screening, spurring ongoing refinement in sensitivity and turnaround time. Reagents such as monoclonal antibodies, antigen preparations, enzymatic catalysts, nucleic acid probes, and recombinant protein standards underpin the efficacy of both instrumentation and assay platforms by ensuring consistency and reproducibility.

From an end-user perspective, diagnostic and forensic laboratories leverage high-complexity systems for comprehensive analyses, while hospitals, clinics, and point-of-care settings prioritize speed and ease of use. Research institutions and academic centers further expand the market by employing specialized assays in drug discovery, genomics, and proteomics research. Across clinical diagnostics, specialist disciplines-cardiology, endocrinology, infectious disease, neurology, and oncology-drive sustained demand for tailored test menus, whereas forensic practitioners rely on blood sample testing, DNA profiling, and toxicology screens. This multilayered segmentation underscores the need for manufacturers to align product roadmaps with the specific workflow requirements and regulatory contexts of each user cohort.

Regional Dynamics Steering the Diagnostic Substances Market

Geographic markets exhibit distinct adoption curves, regulatory environments, and investment priorities that shape the performance of diagnostic substances globally. In the Americas, well-established healthcare infrastructure, centralized reimbursement frameworks, and robust research funding foster rapid uptake of advanced instruments and high-complexity assays. The region’s focus on precision medicine and preventive screening programs underpins sustained capital investment in molecular diagnostics and high-throughput reagent platforms.

Across Europe, the Middle East, and Africa, heterogeneous regulatory regimes and varying healthcare access levels create a mosaic of opportunity. Western European markets lead in regulatory harmonization and reimbursement support for companion diagnostics, while emerging economies in Eastern Europe and parts of Africa demonstrate growing demand for cost-effective point-of-care solutions. The Middle East’s strategic investments in healthcare modernization further expand prospects for centralized laboratories and imaging facilities.

The Asia-Pacific region represents the fastest-growing market segment, driven by large patient populations, government initiatives to bolster domestic biotech production, and escalating expenditures on healthcare infrastructure. Rapid urbanization and rising incidence of chronic diseases are fueling demand for immunoassays, rapid test kits, and next-generation sequencing services. Local champions are increasingly partnering with international technology providers to co-develop tailored reagents and instruments, underscoring the region’s transition from contract manufacturing to innovation leadership.

Competitive Landscape: Leading Players and Strategic Moves

The competitive landscape in the diagnostic substances sector is defined by a cohort of established multinationals and agile innovators competing on technology breadth, supply chain resilience, and customer support. Industry leaders continuously expand their portfolios through targeted acquisitions of niche assay developers, strategic alliances with antibody manufacturers, and cross-sector collaborations integrating digital health solutions.

Market incumbents leverage global distribution networks and service infrastructures to maintain customer loyalty, while emerging companies focus on differentiated offerings such as ultra-sensitive reagents, point-of-care automation, and cloud-enabled analytics. Strategic investment in research and development remains a key differentiator, with top performers allocating significant resources to next-generation sequencing enhancements, microfluidics integration, and novel biomarker discovery. Partnerships between reagent suppliers and instrument manufacturers further streamline product interoperability, enabling end users to deploy comprehensive solutions that deliver consistent performance and rapid results.

Strategic Imperatives for Industry Leaders in Diagnostic Substances

Industry leaders should pursue a multi-pronged strategy to capitalize on evolving market dynamics and mitigate emerging risks. First, diversifying manufacturing footprints to include tariff-exempt regions will enhance supply chain agility and reduce exposure to protectionist policies. Concurrently, accelerating investment in molecular diagnostic platforms and high-sensitivity reagent technologies will position companies to capture expanding demand in oncology, infectious disease, and genetic testing.

Second, integrating digital tools-such as cloud-based data management and AI-driven analytics-into diagnostic workflows can improve throughput, optimize reagent usage, and enhance interpretive accuracy. Third, forging collaborative partnerships across the value chain, including reagent developers, instrument OEMs, and healthcare providers, will accelerate product validation and facilitate seamless market entry. Finally, engaging proactively with regulatory bodies to secure expedited approvals and favorable reimbursement pathways will ensure that innovative diagnostics achieve rapid adoption in high-value markets.

Robust Methodology Underpinning Market Insights

This analysis synthesizes a rigorous combination of secondary research, primary expert interviews, and quantitative data modeling. Secondary sources include peer-reviewed journals, regulatory filings, industry white papers, and trade publications. Complementing this, in-depth interviews with senior R&D executives, regulatory consultants, and end-user procurement managers provided qualitative insights into technology adoption trends and purchasing behaviors.

Quantitative estimates were derived using a bottom-up approach, aggregating unit shipments, reagent consumption volumes, and installed base metrics across geographic and application segments. Triangulation against proprietary shipment databases and financial disclosures ensured accuracy. The research process also incorporated a validation phase, during which draft findings were vetted by an advisory panel of subject-matter experts to confirm relevance and reliability. Robust data governance protocols were followed throughout to maintain consistency and transparency in methodology.

Synthesis of Market Findings and Future Outlook

The diagnostic substances market is characterized by continuous innovation, diverse segmentation, and dynamic regional variations. Advanced instruments and precision reagents enable deeper molecular insights, while assay kits offer accessible solutions for decentralized testing. Trade policies have introduced new supply chain considerations, prompting both challenges and opportunities for regional manufacturing expansion.

Looking ahead, the alignment of digital health platforms with diagnostic workflows will accelerate the shift toward personalized medicine. Regulatory support for companion diagnostics and expedited approvals will further drive adoption of novel assays. Industry participants who embrace methodological rigor in product development, diversify strategically across geographies, and engage collaboratively with stakeholders will be best positioned to capture value. As the diagnostic substances landscape continues to evolve, agile decision-makers will translate comprehensive market understanding into sustainable competitive advantage.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Instruments
      • Analyzers
      • Imaging Equipment
      • Molecular Diagnostic Instruments
        • Next-Generation Sequencing
        • PCR Machines
    • Kits & Assays
      • ELISA Kits
      • Lateral Flow Assays
      • PCR Kits
      • Rapid Test Kits
    • Reagents
      • Antibody Reagents
      • Antigen Reagents
      • Enzymes
      • Nucleic Acid Reagents
      • Recombinant Proteins
  • End-User
    • Diagnostic Laboratories
    • Forensic Laboratories
    • Hospitals & Clinics
    • Point-of-Care Testing Facilities
    • Research & Academic Institutes
  • Application
    • Clinical Diagnostics
      • Cardiology
      • Endocrinology
      • Infectious Diseases
      • Neurology
      • Oncology
    • Forensic
      • Blood Sample Testing
      • DNA Analysis
      • Toxicology
    • Research
      • Drug Discovery
      • Genomics Research
      • Proteomics Research
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Asuragen, Inc. by Bio-Techne Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioLytical Laboratories
  • bioMérieux SA
  • Cepheid by Danaher Corporation
  • DiaSorin S.p.A.
  • Enzo Biochem, Inc.
  • Hitachi Ltd.
  • Hoffmann-La Roche AG
  • Hologic Inc.
  • HyTest Ltd.
  • Illumina Inc.
  • Merck KGaA
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics
  • Qiagen N.V.
  • Quidel Corporation
  • Randox Laboratories Ltd.
  • Sekisui Diagnostics, LLC
  • Siemens AG
  • Sysmex Corporation by TOA Corporation
  • Thermo Fisher Scientific Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diagnostic Substances Market, by Product Type
8.1. Introduction
8.2. Instruments
8.2.1. Analyzers
8.2.2. Imaging Equipment
8.2.3. Molecular Diagnostic Instruments
8.2.3.1. Next-Generation Sequencing
8.2.3.2. PCR Machines
8.3. Kits & Assays
8.3.1. ELISA Kits
8.3.2. Lateral Flow Assays
8.3.3. PCR Kits
8.3.4. Rapid Test Kits
8.4. Reagents
8.4.1. Antibody Reagents
8.4.2. Antigen Reagents
8.4.3. Enzymes
8.4.4. Nucleic Acid Reagents
8.4.5. Recombinant Proteins
9. Diagnostic Substances Market, by End-User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Forensic Laboratories
9.4. Hospitals & Clinics
9.5. Point-of-Care Testing Facilities
9.6. Research & Academic Institutes
10. Diagnostic Substances Market, by Application
10.1. Introduction
10.2. Clinical Diagnostics
10.2.1. Cardiology
10.2.2. Endocrinology
10.2.3. Infectious Diseases
10.2.4. Neurology
10.2.5. Oncology
10.3. Forensic
10.3.1. Blood Sample Testing
10.3.2. DNA Analysis
10.3.3. Toxicology
10.4. Research
10.4.1. Drug Discovery
10.4.2. Genomics Research
10.4.3. Proteomics Research
11. Americas Diagnostic Substances Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Diagnostic Substances Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Diagnostic Substances Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Abbott Laboratories
14.3.2. Agilent Technologies Inc.
14.3.3. Asuragen, Inc. by Bio-Techne Corporation
14.3.4. Becton, Dickinson and Company
14.3.5. Bio-Rad Laboratories Inc.
14.3.6. bioLytical Laboratories
14.3.7. bioMérieux SA
14.3.8. Cepheid by Danaher Corporation
14.3.9. DiaSorin S.p.A.
14.3.10. Enzo Biochem, Inc.
14.3.11. Hitachi Ltd.
14.3.12. Hoffmann-La Roche AG
14.3.13. Hologic Inc.
14.3.14. HyTest Ltd.
14.3.15. Illumina Inc.
14.3.16. Merck KGaA
14.3.17. OraSure Technologies, Inc.
14.3.18. Ortho Clinical Diagnostics
14.3.19. Qiagen N.V.
14.3.20. Quidel Corporation
14.3.21. Randox Laboratories Ltd.
14.3.22. Sekisui Diagnostics, LLC
14.3.23. Siemens AG
14.3.24. Sysmex Corporation by TOA Corporation
14.3.25. Thermo Fisher Scientific Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. DIAGNOSTIC SUBSTANCES MARKET MULTI-CURRENCY
FIGURE 2. DIAGNOSTIC SUBSTANCES MARKET MULTI-LANGUAGE
FIGURE 3. DIAGNOSTIC SUBSTANCES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. DIAGNOSTIC SUBSTANCES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. DIAGNOSTIC SUBSTANCES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIAGNOSTIC SUBSTANCES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 76. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 77. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 78. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 79. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 82. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 83. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 84. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 93. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 135. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 143. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 144. GERMANY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 145. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 153. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 154. FRANCE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 165. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 167. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 168. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 169. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 170. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 173. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 174. ITALY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 175. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 177. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 178. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 179. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 180. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 184. SPAIN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 215. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 217. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 218. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 219. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 220. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 223. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 224. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 235. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 236. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 237. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 238. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 239. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 240. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 243. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 244. QATAR DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 245. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 248. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 249. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 250. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 253. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 254. FINLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 263. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 264. SWEDEN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 275. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 278. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 279. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 280. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 283. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 284. EGYPT DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 285. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 286. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 287. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 288. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 289. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 290. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 293. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 294. TURKEY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 305. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 306. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 308. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 309. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 310. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 311. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 312. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 313. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 314. NORWAY DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 315. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 316. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 317. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 318. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 319. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 320. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 322. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 323. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 324. POLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
TABLE 330. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 331. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 332. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 333. SWITZERLAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
TABLE 334. SWITZE

Companies Mentioned

The companies profiled in this Diagnostic Substances market report include:
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Asuragen, Inc. by Bio-Techne Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioLytical Laboratories
  • bioMérieux SA
  • Cepheid by Danaher Corporation
  • DiaSorin S.p.A.
  • Enzo Biochem, Inc.
  • Hitachi Ltd.
  • Hoffmann-La Roche AG
  • Hologic Inc.
  • HyTest Ltd.
  • Illumina Inc.
  • Merck KGaA
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics
  • Qiagen N.V.
  • Quidel Corporation
  • Randox Laboratories Ltd.
  • Sekisui Diagnostics, LLC
  • Siemens AG
  • Sysmex Corporation by TOA Corporation
  • Thermo Fisher Scientific Inc.

Methodology

Methodology DOWNLOAD NOW

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 189.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 259.99 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Diagnostic Substances - Industry Report - Product Image

Diagnostic Substances - Industry Report

  • Report
  • 161 Pages
  • Global
From
EUR$1,324USDGBP
Oral Fluid Testing Market by Application, End User, Technology, Test Panel Size, Drug Class, Collection Device - Global Forecast to 2030 - Product Image

Oral Fluid Testing Market by Application, End User, Technology, Test Panel Size, Drug Class, Collection Device - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Transplant Diagnostics Market by Diagnostic Application, Technology, Organ Type, End User - Global Forecast to 2030 - Product Image

Transplant Diagnostics Market by Diagnostic Application, Technology, Organ Type, End User - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Assay Kits And Reagents), By Test (Blood Tests, Imaging Tests, Molecular Tests), By End-use (Hospitals And Clinics), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Assay Kits And Reagents), By Test (Blood Tests, Imaging Tests, Molecular Tests), By End-use (Hospitals And Clinics), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
EUR$5,950USDGBP
Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
EUR$3,750USDGBP

About the Diagnostic Reagent Market

The Diagnostic Reagent market is a segment of the Diagnostics industry that focuses on the production and sale of reagents used in diagnostic tests. Diagnostic reagents are substances used to detect the presence of a particular disease or condition. They are used in a variety of medical tests, such as blood tests, urine tests, and tissue tests. Diagnostic reagents are typically produced in a laboratory setting and are used to detect the presence of a particular disease or condition. Diagnostic reagents are used in a variety of medical tests, such as blood tests, urine tests, and tissue tests. They are used to detect the presence of a particular disease or condition, and can be used to diagnose a variety of illnesses and conditions. Diagnostic reagents are typically produced in a laboratory setting and are used to detect the presence of a particular disease or condition. The Diagnostic Reagent market is highly competitive, with a number of companies offering a wide range of products. Some of the major players in the market include Abbott Laboratories, Becton Dickinson, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more